Alzheimer's Disease Neuroimmune Resolution and Specialized Pro-Resolving Mediator Companies

📖 Wiki Page

company1160 wordssynced 2026-04-02

AD Neuroimmune Resolution SPM Companies

Overview

flowchart TD companies_ad_neuroimmune_resol["Alzheimers Disease Neuroimmune Resolution and S"] style companies_ad_neuroimmune_resol fill:#4fc3f7,stroke:#333,color:#000 companies_ad_neuroim_0["Key Therapeutic Approaches"] companies_ad_neuroimmune_resol -->|"includes"| companies_ad_neuroim_0 style companies_ad_neuroim_0 fill:#81c784,stroke:#333,color:#000 companies_ad_neuroim_1["Specialized Pro-Resolving Mediator Companies"] companies_ad_neuroimmune_resol -->|"includes"| companies_ad_neuroim_1 style companies_ad_neuroim_1 fill:#ef5350,stroke:#333,color:#000 companies_ad_neuroim_2["Resolvent Biosciences"] companies_ad_neuroimmune_resol -->|"includes"| companies_ad_neuroim_2 style companies_ad_neuroim_2 fill:#ffd54f,stroke:#333,color:#000 companies_ad_neuroim_3["Cardiol Therapeutics"] companies_ad_neuroimmune_resol -->|"includes"| companies_ad_neuroim_3 style companies_ad_neuroim_3 fill:#ce93d8,stroke:#333,color:#000 companies_ad_neuroim_4["Cytos Biotechnology"] companies_ad_neuroimmune_resol -->|"includes"| companies_ad_neuroim_4 style companies_ad_neuroim_4 fill:#4fc3f7,stroke:#333,color:#000 companies_ad_neuroim_5["Neuroimmune Resolution Companies"] companies_ad_neuroimmune_resol -->|"includes"| companies_ad_neuroim_5 style companies_ad_neuroim_5 fill:#81c784,stroke:#333,color:#000

...

AD Neuroimmune Resolution SPM Companies

Overview

Mermaid diagram (expand to render)

This category page covers biotechnology and pharmaceutical companies developing neuroimmune resolution therapies, specialized pro-resolving mediator (SPM) approaches, and pro-resolving cytokine modulators for Alzheimer's disease. Chronic neuroinflammation is a core pathological feature of AD, characterized by ongoing activation of microglia and astrocytes. SPMs — including resolvins, protectins, maresins, and lipoxins — represent a novel therapeutic approach that actively promotes resolution of inflammation rather than simply suppressing it.

Companies targeting this pathway aim to shift the brain's immune state from chronic inflammation to active resolution, protecting neurons, preserving synaptic function, and potentially slowing disease progression.

Key Therapeutic Approaches

| Approach | Description | Companies |
|----------|-------------|-----------|
| SPM Receptor Agonists | Activate G-protein coupled receptors for SPM signaling | Resolvent Biosciences, Omega-3 developers |
| SPM Mimetics | Synthetic analogs of resolvins, protectins, maresins | Cardiol, Cytos |
| Pro-Resolving Cytokine Modulators | Modulate IL-10, TGF-beta for resolution | INmune Bio, Alector |
| NLRP3 Inhibitors | Block inflammasome activation upstream | Nodthera, Cyclo Therapeutics |
| TREM2 Modulators | Enhance microglial phagocytosis and resolution | Alector (AL002), TrueBinding |
| CD47-SIRPalpha Blockade | Enable phagocytic clearance of debris | TrueBinding (TB-006) |

Specialized Pro-Resolving Mediator Companies

Resolvent Biosciences

Focus: SPM receptor agonists for neuroinflammation resolution
Mechanism: Develops synthetic resolvins and protectins that activate G-protein coupled receptors (ALX/FPR2, GPR32) to trigger active inflammation resolution
Indication: Alzheimer's disease, other neurodegenerative conditions
Stage: Research/lead optimization
Notes: Pioneer in SPM receptor pharmacology; platform spans multiple SPM analogs and receptor targets
Key Targets: ALX/FPR2, GPR32, resolvin D1, resolvin D2, protectin D1

Cardiol Therapeutics

Focus: SPM mimetics and anti-inflammatory approaches
Lead Candidate: CardiolRx (CBD formulation)
Mechanism: Anti-inflammatory properties through multiple pathways including SPM promotion; modulates neuroimmune response
Indication: Alzheimer's disease, cardiac inflammation
Stage: Phase 2 (cardiac), preclinical (AD)
Notes: Leverages anti-inflammatory properties of cannabinoids for neuroimmune modulation
Key Targets: CB2 receptor, inflammatory cytokines, SPM pathways

Cytos Biotechnology

Focus: SPM mimetics and immunomodulation
Mechanism: Developing synthetic SPM analogs for enhanced stability and potency compared to endogenous SPMs
Indication: Alzheimer's disease, inflammatory conditions
Stage: Research
Notes: Swiss biotech with expertise in immunomodulatory approaches
Key Targets: SPM receptors, inflammatory resolution

Neuroimmune Resolution Companies

INmune Bio

Focus: Pro-resolving cytokine and complement modulation
Lead Candidate: XPro1595 (DN-TNF inhibitor)
Mechanism: Selective inhibition of soluble TNF (not membrane TNF) to reduce neuroinflammation while preserving immune surveillance; promotes pro-resolving state
Indication: Alzheimer's disease
Stage: Phase 2
Notes: Phase 1 data showed reduction in neuroinflammatory biomarkers. Novel approach targeting chronic inflammation without suppressing normal immune function
Clinical Trials: Phase 2 in AD patients with elevated inflammatory markers
Key Targets: Soluble TNF, neuroinflammation, cognitive function

Nodthera

Focus: NLRP3 inflammasome inhibitors
Lead Candidate: NT-0796
Mechanism: Oral NLRP3 inhibitor blocking upstream inflammasome activation; reduces IL-1beta and IL-18 production
Indication: Alzheimer's disease, inflammatory diseases
Stage: Phase 1
Notes: First oral NLRP3 inhibitor to enter the clinic for AD; addresses upstream driver of chronic neuroinflammation
Key Targets: NLRP3, IL-1beta, IL-18, inflammasome

Cyclo Therapeutics

Focus: NLRP3 inhibition and metabolic approaches
Lead Candidate: Trappsol (cyclodextrin)
Mechanism: Broad anti-inflammatory effects including NLRP3 inhibition; also addresses cholesterol metabolism and lysosomal function
Indications: Alzheimer's disease, Niemann-Pick disease
Stage: Phase 2/3 (NPC), Phase 2 (AD planned)
Notes: Longstanding development for rare diseases now expanding to AD; broad mechanism offers multiple benefits
Key Targets: NLRP3, lysosomal function, cholesterol transport

Alector

Focus: TREM2 modulators and neuroimmune checkpoint
Lead Candidate: AL002 (TREM2 agonist)
Mechanism: Activates TREM2 on microglia to enhance phagocytic clearance of amyloid and debris; promotes neuroprotective microglial state
Indication: Alzheimer's disease
Stage: Phase 2
Notes: Leading TREM2 program; INteRhYthM trial in early AD. TREM2 variants associated with AD risk, making this a genetically validated target
Clinical Trials: INteRhYthM Phase 2 study
Key Targets: TREM2, microglial activation, amyloid clearance

TrueBinding

Focus: CD47-SIRPalpha blockade for immune clearance
Lead Candidate: TB-006
Mechanism: Blocks CD47-SIRPalpha "don't eat me" signal to enable microglial phagocytosis of amyloid plaques and damaged cells
Indication: Alzheimer's disease
Stage: Phase 1/2
Notes: Novel mechanism enabling active clearance; addresses the neuroimmune checkpoint that prevents debris removal
Key Targets: CD47, SIRPalpha, phagocytic clearance

SPM and Omega-3 Derived Approaches

Focus: Converting omega-3 fatty acids (EPA, DHA) to SPMs in vivo or delivering SPMs directly
Mechanism: Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are precursors to resolvins, protectins, and maresins
Notes: Several approaches:
High-dose omega-3 to increase endogenous SPM production
SPM analog delivery (more stable than endogenous compounds)
Enzyme modulators to enhance SPM conversion

Pipeline Overview

| Company | Candidate | Mechanism | Stage | Indication |
|---------|-----------|-----------|-------|------------|
| INmune Bio | XPro1595 | Soluble TNF inhibitor | Phase 2 | AD |
| Nodthera | NT-0796 | NLRP3 inhibitor | Phase 1 | AD |
| Alector | AL002 | TREM2 agonist | Phase 2 | AD |
| TrueBinding | TB-006 | CD47 blockade | Phase 1/2 | AD |
| Cyclo | Trappsol | NLRP3/lysosomal | Phase 2 | AD |
| Resolvent | SPM agonists | SPM receptor agonist | Research | AD |
| Cardiol | CardiolRx | SPM promotion | Preclinical | AD |

Scientific Rationale

Neuroinflammation in AD is characterized by:

Chronic microglial activation surrounding amyloid plaques
Elevated pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alpha)
Reduced anti-inflammatory and pro-resolving mediators
Impaired phagocytic clearance of amyloid and cellular debris

The resolution of inflammation is an active process mediated by SPMs:

Resolvins (from omega-3): Potent pro-resolving mediators
Protectins (from DHA): Neuroprotective and pro-resolving
Maresins (from DHA): Promote tissue repair and resolution
Lipoxins (from arachidonic acid): Endogenous resolution mediators

SPMs act through G-protein coupled receptors (ALX/FPR2, GPR32, GPR18) to:

Block neutrophil infiltration
Promote macrophage/microglial phagocytosis
Reduce cytokine production
Enhance clearance of cellular debris
Support tissue repair

TREM2 plays a critical role in microglial response to amyloid; genetic variants affecting TREM2 function increase AD risk, validating this as a therapeutic target[@trem2_pathway].

References

[Neuroinflammation in AD (Nature Reviews Neuroscience, 2023)](https://www.nature.com/articles/s41582-023-00789-0)

[SPMs in neurodegenerative diseases (Brain Behavior and Immunity, 2024)](https://www.sciencedirect.com/journal/brain-behavior-and-immunity)

[TREM2 and neuroimmune signaling (Neuron, 2023)](https://www.cell.com/neuron)

[Targeting IL-1 in AD (Alzheimer's & Dementia, 2022)](https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12594)

Alzheimer's Disease Neuroimmune Resolution and Specialized Pro-Resolving Mediator Companies

AD Neuroimmune Resolution SPM Companies

Overview

AD Neuroimmune Resolution SPM Companies

Overview

Key Therapeutic Approaches

Specialized Pro-Resolving Mediator Companies

Resolvent Biosciences

Cardiol Therapeutics

Cytos Biotechnology

Neuroimmune Resolution Companies

INmune Bio

Nodthera

Cyclo Therapeutics

Alector

TrueBinding

SPM and Omega-3 Derived Approaches

Multiple Companies Developing SPM-Related Approaches

Pipeline Overview

Scientific Rationale

References

See Also